Submitted by Cássia Santos (cassia.bcufg@gmail.com) on 2014-08-06T11:34:54Z
No. of bitstreams: 2
license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5)
Estudo_da_Encapsulacao_da_isotretinoina_nas_formas_livres_e_associada_a_ciclodextrinas_em_niossomas.pdf: 2030155 bytes, checksum: 19eecf0e1e4b0f42b01d0975d4634686 (MD5) / Made available in DSpace on 2014-08-06T11:34:54Z (GMT). No. of bitstreams: 2
license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5)
Estudo_da_Encapsulacao_da_isotretinoina_nas_formas_livres_e_associada_a_ciclodextrinas_em_niossomas.pdf: 2030155 bytes, checksum: 19eecf0e1e4b0f42b01d0975d4634686 (MD5)
Previous issue date: 2009-12-15 / Conselho Nacional de Pesquisa e Desenvolvimento Científico e Tecnológico - CNPq / Fundação de Apoio à Pesquisa - FUNAPE / Non-ionic surfactant vesicles (niosomes) and cyclodextrins (CDs) are able to modify
physical-chemical properties of incorporated drugs. One of the major challenges for
the topical administration of retinoids, such as isotretinoin (31cisRA), is the stability of
these compounds in formulations capable of reducing their toxicity during the
treatment. The purpose of this research was to develop vesicular carries capable to
transport and deliver isotretinoin for topical application during acne treatment. The
niosomes were obtained from Bryj®30:Cholesterol:DCP (50:25:10) by the film
hydration method. The HP CDs:isotretinoin complex was obtained by agitation for 8
days in phosphate buffer pH 7.4. The vesicles were characterized and it was
possible to encounter a large amount of morphological varieties, flexible structures
and fluid membrane, after inclusion of free isotretinoin. The fluidness of the
membrane that contains isotretinoin allowed leaking of the drug when in
concentration above 5 mM. The HP CDs:Isotretinoin (20:1) increased the vesicle
size considerably, also allowing drug leaking. The systems developed presented
themselves as potential carries of isotretinoin for topical application and played the
roll of drug delivery system, / Os niossomas, vesículas formadas por tensoativos não-iônicos, e as ciclodextrinas
(HP CDs) são sistemas capazes de alterar as características físico-químicas
originais de diversos fármacos. O maior desafio da administração tópica de
retinóides, como isotretinoína (ácido 13-cis-retinóico), é a manutenção de sua
estabilidade em formulações capazes de reduzir a sua toxicidade durante o
tratamento. A proposta deste trabalho foi desenvolver sistema para o transporte e
liberação da isotretinoína com potencial para aplicação na terapêutica tópica da
acne. Os niossomas foram formados a partir de Brij®30:Colesterol:DCP (50:25:10)
pelo método de hidratação do filme lipídico. O complexo HP Ciclodextrinasisotretinoína
foi obtido por agitação durante 8 dias em tampão fosfato pH 7,4. Os
niossomas foram caracterizados sendo possível verificar grande variedade
morfológica, estruturas flexíveis e membrana fluída após a inclusão da isotretinoína
livre. A fluidez da membrana que contém isotretinoína permitiu o vazamento de
fármaco quando em concentrações maiores que 5 mM. O complexo
HP CDs:isotretinoína (20:1) aumentou consideravelmente o tamanho das vesículas,
também permitindo vazamentos. Os sistemas desenvolvidos possuem potencial
para uso como carreadores da isotretinoína na aplicação tópica demonstrando
comportamento de “sistema de liberação modificado”.
Identifer | oai:union.ndltd.org:IBICT/oai:repositorio.bc.ufg.br:tde/2886 |
Date | 15 December 2009 |
Creators | Rodovalho, Luciana Ferreira Fonseca |
Contributors | Lima, Eliana Martins |
Publisher | Universidade Federal de Goiás, Programa de Pós-graduação em Ciências Farmacêuticas (FF), UFG, Brasil, Faculdade Farmácia - FF (RG) |
Source Sets | IBICT Brazilian ETDs |
Language | Portuguese |
Detected Language | Portuguese |
Type | info:eu-repo/semantics/publishedVersion, info:eu-repo/semantics/masterThesis |
Format | application/pdf |
Source | reponame:Biblioteca Digital de Teses e Dissertações da UFG, instname:Universidade Federal de Goiás, instacron:UFG |
Rights | http://creativecommons.org/licenses/by-nc-nd/4.0/, info:eu-repo/semantics/openAccess |
Relation | 824936988196152412, 600, 600, 600, 600, 600, 6010281161524209375, 6997636413449754996, -2555911436985713659, -8644727573657825680, AHFS – DRUG INFORMATION. Skin and mucous membrane agentes: miscellaneous skin and mucous membrane agentes. Bthesda: AHFS, p. 2958- 2963, 1998. AGGARWAL D., PAL D., MITRA A. K., KAUR I. P. Study of the extent of ocular absorption of acetazolamide from a developed niosomal formulation, by microdialysis sampling of aqueous humor. International Journal of Pharmaceutics, Amsterdan, v. 338, p. 21-26, 2007. AKTAN S., OZMEN E., SANLI B. Anxiety, depression and nature of acne vulgaris in adolescents. International Journal of Dermatology, Philadelphia, v. 23, p. 354-357, 2000. ANDREO-FILHO N., ODA C. Y., SCARPA M. V., OLIVEIRA A. G. Quantitative determination of phosphatidylcholine by high performance liquid chromatography using silica column. Revista de Ciências Farmacêuticas, São Paulo, v. 20, p.107-115, 1999. ANJOS, J. L. V., NETO D. S., ALONSO A. Efects of ethanol/L-menthol on the dynamics and partitioning of spin-labeled lipids in the stratum corneum. Brazil. European Journal of Pharmaceutics and Biopharmaceutics, Stuttigart, v.67, p.406–412, 2007. ALLEN , L. G., BLOXHAN, D. P. The pharmacology and pharmakocinetcs of the retinoids. Pharmac. Ther., Oxford, V.40, n. 1, p. 1-27, 1989. ALONSO A, DE QUEIROS WP, NETO DD. Dynamics and partitioning of spinlabeled stearates into the lipid domain of stratum corneum. Journal of Controlled Release, Amsterdan, v. 106, p. 374-385, 2005. ALVES C.P.I., LIMA. E.M. Estudo e caracterização da encapsulação de isotretinoína em lipossomas unilamelares. Dissertação de mestrado. Faculdade de Farmácia. Universidade Federal de Goiás. 2005. ANSARI M., KAZEMIPOUR M., AKLAMLI M. The study of drug permeation through natural membranes. International Journal of Pharmaceutics, Amsterdan, v. 327, p. 6–11, 2006. ANVISA. Guia para validação de métodos analíticos e bioanalíticos. Agência Nacional de Vigilância Sanitária. Resolução-Re Nº 899, de 29 de Maio de 2003 – Disponível em: www.anvisa.gov.br AOKI H., TOTTORI T., SAKURAI F., FUJI K., MIYAJIMA K. Effects of positive charge density on the liposomal surface on disposition kinetics of liposomes in rats. International Journal of Pharmaceutics, Amsterdan, v. 156, p. 163-174, 1997. AZEVEDO M. Nanoesferas e a liberação controlada de fármacos. LCES, UNICAMP. 2002. Disponível em: www.lqes.iqm.unicamp.br BABU R.J., PANDIT J.K.. Effect of penetration enhancers on the release and skin permeation of bupranolol from reservoir-type transdermal delivery systems. International Journal of Pharmaceutics. Amsterdan, v. 288, p. 325–334, 2005. BETZ G. ET AL. In vivo comparison of various liposome formulations for cosmetic application. International Journal of Pharmaceutics, Amsterdan, v. 296, p. 44-54, 2005. BIGBY, M : STERN, R S. Adverse reactions to isotretinoin. A report from the Adverse Drug Reaction Reporting System. Journal of the American Academy of Dermatology, St. Louis, v. 18, p. 543-552, 1988. BIWER, A.; ANTRANIKIAN, G.; HEINZLE, E. Enzimatic prodution of cyclodextrins. Appl. Microbiology and Biotechnology, Heidelberg, v.59, p.609-617, 2002. CHALKER D., LESHER J., SMITH J. Efficacy of topical isotretinoína 0,05% gel in acne vulgaris: results of multicenter double-blind investigation. Journal of the American Academy of Dermatology, St. Louis, v. 17, p. 251-254, 1987. CIOLA R. Fundamentos da Cromatografia Líquida de Alto Desempenho: HPLC. 1º edição, São Paulo, Edgar Blücher, 2003. CODERCH L., FONOLLOSA J., DE PERA M., ESTELRICH J., DE LA MAZA A. Influence of cholesterol on liposome fluidity by EPR Relationship with percutaneous absorption. Journal of Controlled Release, Amsterdan, v. 68, p. 85– 95, 2000. CORTESI R., ESPOSITO E., CORRADINI F., SIVIERI E., DRECHSLER M., ROSSI A., SCATTURIN A., MENEGATTI E. Non-phospholipid vesicles as carriers for peptides and proteins: Production, characterization and stability studies. International Journal of Pharmaceutics. Amsterdan, v. 339, p. 52– 60, 2007. DEMICHELI C. FRÉZARDI F.,SCHETTINI D. A. ROCHA. O.G.F. Lipossomas: propriedades físico-químicas e farmacológicas, aplicações na Quimioterapia à base de antimônio. Quim. Nova, Vol. 28, No. 3, 511-518, 2005. DINIZ D., LIMA E., ANTONIOSI FILHO N. Isotretinoína: perfil farmacológico, farmacocinético e analítico. Brasilian Journal of Pharmaceutical Sciences. v. 38, n. 4, p. 415 – 430, 2002. DRUGDEX – DRUG EVALUATIONS. Isotretinoin. Disponível em: http://www.edrompro.com.br/ufg. Acesso em: 26 mar 2001. DUCHÊNE, D., WOUESSIDJEWE D. Pharmaceutical and medical applications of cyclodextrins. In: Polysaccharides in medicinal applications. Marcel Dekker, New York, p. 575-602, 1996. DUNCAN R. Nanomedicine – gets clinical. Nanotoday, August 2005. ELLIS C. N., KRACH K. J. Uses and complications od isotretinoin therapy. Journal of the American Academy of Dermatology, St. Louis, v. 45 n. 5 p. S150-S156, 2001. ESF, Scientific Forward Look on Nanomedicine. European Science Foundation Policy Briefing, February 23, 2005. Disponível em: www.esf.org Acesso em: fevereiro/ 2007. FAHMY T. M., FONG P. M., GOYAL A., SALTZMAN W. M. Targeted for drug delivery. Materials Today, v. 8, p. 18-26, 2005. FDA - Guidance for Industry Topical Dermatological Drug Product NDAs and ANDAs — In Vivo Bioavailability, Bioequivalence, In Vitro Release and Associated Studies. 1998. Disponível em: http://www.fda.gov/CDER/guidance/4592fnl.pdf: j:\!guidanc\2481dft.wpd. FREITAS, R.A. Nanotechnology, nanomedicine and nanosurgery. International Journal of Surgery, London, v. 3, p. 243-246, 2005. FONSECA, A., PRISTA, L. N. Manual de terapêutica dermatológica e cosmetologia. São Paulo: ROCA, p. 129, 273, 1993. GIANASI E., COCIANCICH F., UCHEGBU I. F., FLORENCE A. T., DUNCAN R. Pharmaceutical and biological characterisation of a doxorubicin-polymer conjugate (PK1) entrapped in sorbitan monostearate Span 60 niosomes. International Journal Pharrnaceutics, Amsterdan, v. 148, p. 139-148, 1997. GILCHREST B.A. Retinoids and photodamage. British Journal of Dermatology, Oxford, v. 127, p. 14-20, 1992. GIRIGOSWAMI A., DAS S. DE S. Flororescence and dinamic light scattering of niosomes-membrane mimetic systems. Spectrochimica Acta Part A, Oxford, v. 64, p. 859-866, 2006. GOLLNICK ET AL. Management of acne – a report from a global alliance to improve outcomes in acne. Journal of the American Academy of Dermatology, St. Louis, v. 49, n. 1, p. S1-S37, 2003. HAIT S. K., MOULIK S. P.. Determination of Critical Micelle Concentration (CMC) of Nonionic Surfactants by Donor–Acceptor Interaction with Iodine and Correlation of CMC with Hydrophile–Lipophile Balance and Other Parameters of the Surfactants. Journal of Surfactants and Detergents, v. 4, no. 3, 2001. HUGHES B., NORRIS J., CUNLIFFE W. A double-blind evaluation of topical isotretinoína 0,05%, benzoyl peroxide gel 5% and placebo in patients with acne. Clinical and Experimental Dermatology, Oxford, v. 17, p. 165-168, 1992. ICH - VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY Q2(R1). Current Step 4 version Parent Guideline dated 27 October 1994 (Complementary Guideline on Methodology dated 6 November 1996 incorporated in November 2005). KEMPS J.M.A., CROMMELIN D.J.A. Chemische stabiliteit van fosfolipiden in farmaceutische preparaten. I. Hydrolyse van fosfolipiden in waterig milieu. Journal of Pharmaceutical Weekbl, v. 123, p. 355–363, 1988. KLIBANOV A. L., MARUYAMA K., BECKERLEG A. M., TORCHILIN V. P., HUANG L. Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. Biochimica et Biophysica Acta (BBA) - Biomembranes, Amsterdan, v. 1062, p. 142-148, 1991. KOO M. O. ET AL. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomedicine: Nanotechnology, Biology and Medicine, New York, p. 193-212, 2005. JOHNSON E. M. A risk assessment of topical tretinoin as a potential human developmental toxin based on animal and comparative human data. Journal of the American Academy of Dermatology, St. Louis, v. 36, n. 3, p. S86-S90, 1997. LEBOWITZ M.A., BERSON D.S. Ocular effects of oral retinoids. Journal of the American Academy of Dermatology, St. Louis, v. 19, p. 209-211, 1988. LIMA E.M., DINIZ D.G.A, ANTONIOSI-FILHO N.R. Development of a gas chromatography method for the determination of isotretinoin and its degradation products in pharmaceuticals. Journal of Pharmaceutics - Biomedical Analysis, Oxford, v. 38, p. 678–685, 2005. LIN HS, LEONG W. W. Y., TANG J. A., LEE P., CHAN S. Y., HO P. C. Biopharmaceutics of 13-cis-retinoic acid (isotretinoin) formulated with modified b-cyclodextrins, Int. J. Pharmaceut. (2007), doi:10.1016/j.ijpharm.2007.03.050 LIU X., LIN H., THENMOZHIYAL J. C., CHAN S. Y., HO P. C. Inclusion of acitretin into cyclodextrins: Phase solubility, photostability, and physicochemical characterization. Journal of Pharmaceutical Sciences, Easton, v. 92, p. 2449 – 2457, 2003. LIU X., LIN H., CHAN S. Y., HO P. C. Biopharmaceutics of -cyclodextrin derivative-based formulations of acitretin in sprague-dawley rats. Journal of Pharmaceutical Sciences, Easton, v. 93, p. 805 – 815, 2004. LOFTSSON T., BREWSTER M. E. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. Journal of Pharmaceutical Sciences, Easton, v. 85, p. 1017-1024, 1996. LOWENSTEIN E.J. Isotretinoin made SMART and simple. Cutis, New York, v. 70, p. 115-120, 2002. MACHY P., LESERMAN L. Les liposomes en biologie cellulaire et pharmacologie. Les Edition Inserm. John Libbey Eurotext. p. 1-25, 1987. MAESTRELLI ET AL. Preparation and characterization of liposomes encapsulating ketoprofen-cyclodextrin complexes for transdermal drug delivery. International Journal of Pharmaceutics, Amsterdan, v.208, p. 55-67, 2005. MALLON E., NEWTON J.N., KLASSEN A., STEWART-BROWN S.L., RYAN T.J., FINLAY A.Y. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. British Journal of Dermatology, Oxford, v. 140, p. 672-676, 1999. MANCONI M., SINICO C., VALENTI D., LOY G., FADDA A. M. Niosomes as carriers for tretinoin. I. Preparation and properties. International Journal of Pharmaceutics, Amsterdan, v. 234, p. 237–248, 2002. MANCONI M., VELENTI D., SINICO C. Niosomes as carries for tretinoin. II. Influence of vesicular incorporation on tretinoin photostability. International Journal of Pharmceutics, Amsterdan, v. 260, p. 261-272, 2003. MANCONI M., SINICO C., VELENTI D., LAI F., FADDA A. Niosomes as carries for tretinoin. III. A study into the in vitro cutaneos delivery vesicle-incorporated tretinoin. International Journal of Pharmceutics, Amsterdan, v. 311, p. 11 - 19, 2006. MANOSROI, A., WONGTRAKUL, P., MANOSROI, J., SAKI, H., SUGAWARA, F., YUASA, M., ABE, M.,. Characterization of vesicles prepared with various nonionic surfactants mixed with cholesterol. Biointerfaces. Amsterdan, v. 30, p. 129– 138, 2003. MEZEI M., GULASEKHARAM V. Liposomes - a selective drug delivery system for the topical route of administration I. Lotion dosage form. Life Sciences, Oxford, v. 26, p. 1473-1477, 1980. MISHRA D., MISHRA P. K., DUBEY V. V., DABADGHAO S., JAIN N. K. Evaluation of uptake and generation of immune response by murine dendritic cells pulsed with hepatitis B surface antigen-loaded elastic liposomes. Vaccine, Amsterdan, xxx, 2007. MONTASSIER P., DUCHÊNE D., POELMAN MC.. Inclusion complexes of tretinoína with cyclodextrins. International Journal of Pharmaceutics, Amsterdan, v. 153, p. 199-209, 1997. NAIDOO K.J., CHEN J.YJ., JANSSON J. L. M., WILDMALM G., MALINIAK A.. Molecular Properties Related to the Anomalous Solubility of -Cyclodextrin. Journal of Physics and Chemistry, v. 108, p. 4236-4238, 2004. NASSERI B. Effect of cholesterol and temperature on the elastic properties of niosomal membranes. International Journal of Pharmaceutics, Amsterdan, v. 300, p. 95 – 101, 2005. NASCIMENTO JR. C. S., SANTOS H. F., ALMEIDA W. A. Theoretical study of the formation of the a-cyclodextrin hexahydrate. Chemical Physics Letters, Amsterdan, v. 397 p. 422-428, 2004. ODOM R. Managing actinic keratoses with retinoids. Journal of the American Academy of Dermatology, St. Louis, v.132, p. 519-526, 1998. ORGANIZACIÓN MUNDIAL DE LA SALUD. Acne vulgar. In: Modelo OMS de información sobre prescriptión de medicamentos: Medicamentos utilizados em las enfermidades cutâneas. Genebra: OMS, 1999, p. 59-63. OSTRO M. J.,CULLIS P. R. Use of liposomes as injectable-drug delivery systems. American Journal of Hospital Pharmacy, Bethesda, v. 46, p. 1576- 1587, 1989. PARDAKTHY A., VARSHOSAZ J., ROUHOLAMINI A., In vitro of polyoxyethylene alkyl ether niosomes for delivery of insulin. International Journal of Pharmaceutics, Amsterdan, v. 328, 130-141. 2007. PERSHING L.K., NELSON J.L., CORLETT J.L., ET AL. Assessment of a dermatopharmacokinetic approach in the bioequivalence determination of topical tretinoin gel products. Journal of the American Academy of Dermatology, St. Louis, v. 48, p. 740-751, 2003. PIRARD G.E., KLIGMAN A.M., STOUDEMAYER T., LEVEQUE J.L. Comparative effects of retinoic acid, glycolic acid and a lipophilic derivative of salicylic acid of photodamaged epidermis. Journal of Dermatology, v. 199 p. 50-53, 1999. QI H. Z., SIKORSKI C. T. Controlled delivery using cyclodextrin technology. Pharmaceutical Technology European, v. 13, p. 17-27, 2001. QUEILLE-ROUSSEL C., PONCET M., MESAROS S., CLUCAS A., BAKER M., SOLOFF A.M. Comparison of the cumulative irritation potential of adapalene gel and cream with that of erythromycin / tretinoin solutions and gel and erythromycin / isotretinoin gel. Clinical therapeutics, Princenton, v. 23, n. 2, 2001. RAJEWSKI R. A., STELLA V. J. Pharmaceutical applications of cyclodextrins. 2. in vivo drug delivery. Journal of Pharmaceutical Sciences, Easton, v. 85, p. 1142 – 1169, 2000. RAMA A.C., VEIGA F., FIGUEIREDO I.V., SOUZA A., CARAMONA M.. Biopharmaceutical aspects of drug formulation for neonatology. Rational for indomethacin's complexation with hydroxypropyl- -cyclodextrin to treat patent ductus arteriosus. Revista Brasileira de Ciências Farmaceuticas, v.41, n.3, 2005. RIGOPOULOS, D. ET AL. Comparison of topical retinoids in the treatment of acne. Clinics in Dermatology, New York, v. 22, p. 408-411, 2004. SANTANA D. P. Evaluation biopharmaceutique de diferents formulation galeniques de l’isotretinoine en gel. Domaine de la Merci. La Tonche. 1992. SAURAT, J.H. Oral isotretinoin. Where now, where next? Dermatology Basel, Basel, v. 195, n. 1, p. 1-3, 1997. SESSA G., WEISSMANN G. Phospholipid spherules (liposomes) as a model for biological membranes. Journal of Lipid Research, Memphis, 9:310- 318, 1968. SHALITA A. R. Acne: Clinical presentations. Clinics in dermatology, New York, v. 22, p. 385-386, 2004. SIGMA ALDRICH – Catálogo Eletrônico. Disponível em: http://www.sigmaaldrich.com/catalog/search/ProductDetail/SIAL/P1254 . Acesso em: Janeiro2006 SINICO C, MANCONI M., PEPPI M., LAI F., VALENTI D., FADDA A. M. Liposomes as carriers for dermal delivery of tretinoin: in vitro evaluation of drug permeation and vesicle–skin interaction. Journal of Controlled Release. Amsterdan, v. 103, p. 123–136, 2003. STELLA V.J., RAJEWSKI R. A. Cyclodextrins: their future in drug formulation and delivery. Pharmaceutical Research, Stuttgart, v. 14, p. 556-567, 1997. STELLA V.J., RAO M. V., ZANNOU E.A., VAHID ZIA. Mechanisms of drug release from cyclodextrin complexes. Advanced Drug Delivery Reviews, Amsterdan, v.36, p.3–16, 1999. SUKOWSKI W. W., PENTAK D., NOWAK K., SUKOWSKA A. The influence of temperature and pH on the structure of liposomes formed from DMPC. Journal of Molecular Structure, Amsterdan, v. 792–793, p. 257–264, 2006. SZEJTLI, J. Cyclodextrin inclusion complexes. In: SZEJTLI, J. Ed. Cyclodextrin Technology. London: Kluwer Academic Publishers, p. 79- 185., 1988. SZEJTLI, J. The cyclodextrins and their applications in biotechnology. Carbohydrate Polymers. Budapest, v. 12, p. 375-392, 1990. TABBAKHIAN M., TAVAKOLI N., JAAFARI M. R., DANESHAMOUZA S. Enhancement of follicular delivery of finasteride by liposomes and niosomes 1. In vitro permeation and in vivo deposition studies using hamster flank and ear models. International Journal of Pharmaceutics, Amsterdan, v. 323, p. 1-10. 2006. TAN X., MELTZER N., LINDENBAUM S. Determination of the kinetics of degradation of 13-cis-retinoic acid and all-trans-retinoic acid in solution. Journal of Pharmaceutical and Biomedical Analysis, Oxford, v. 11, p. 817-822, 1993. TORCHILIN V. P. Multifunctional nanocarriers. Advanced Drug Delivery Reviews, Amsterdan, v. 58, p. 1532–1555, 2006. USP 30 – NF 25 – United States Pharmacopeial Convention Inc., Rockville, 2007. UCHEGBU, I.F., VYAS, S.P., Non-ionic surfactant based vesicles (niosomes) in drug delivery. International Journal of Pharmaceutics, Amsterdan, v. 172, p. 33–70, 1998. VEMURI S., RHODES C. T. Preparation and characterization of liposomes as therapeutic delivery systems: a review. Pharmaceutica Acta Helvetiae. Zurich, v. 70, p. 95-111, 1995. WEINER A. L. Liposomes as carriers for polypeptides. Advanced Drug Delivery Reviews, Amsterdan, v. 3, p. 307-341, 1989. YAP K.L., LIU X., THENMOZHIYAL, HO P.C. Characterization of the 13-cisretinoic acid / cyclodextrin inclusion complexes by phase solubility, photostability, physicochemical and computational analysis. European Journal of Pharmaceutical Sciences, Amsterdan, v. 25 p. 49-56, 2005. |
Page generated in 0.0034 seconds